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AC

:   adenocarcinoma

NGF

:   nerve growth factor

*NTRK1*

:   neurotrophin receptor tyrosine kinase 1

p75^NTR^

:   p75 neurotrophin receptor

proNGF

:   NGF precursor

SCC

:   squamous cell carcinoma

TMA

:   tissue microarray

1. INTRODUCTION {#fba21143-sec-0001}
===============

Cervical cancer represents 7% of female cancers worldwide.[^1^](#fba21143-bib-0001){ref-type="ref"} Histological subtypes are divided into the predominant squamous cell carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (AC/ASC), accounting for about 75% and 25% of all cases, respectively.[^2^](#fba21143-bib-0002){ref-type="ref"} Despite a decrease in incidence and disease‐specific mortality worldwide, 50% of cervical cancer patients in developing countries and over 10% in developed countries are diagnosed with late stage disease.[^3^](#fba21143-bib-0003){ref-type="ref"}, [^4^](#fba21143-bib-0004){ref-type="ref"} The presence of distant metastases indicates a worse prognosis (median survival of 8‐13 months),[^5^](#fba21143-bib-0005){ref-type="ref"} and the development of novel diagnostic, prognostic, and therapeutic strategies for clinically advanced cervical cancers is warranted.

Nerve growth factor (NGF) is well described for its role in the development of the nervous system.[^6^](#fba21143-bib-0006){ref-type="ref"} NGF drives neuronal outgrowth (axonogenesis) during development by activating the receptor tyrosine kinase TrkA (also called neurotrophin receptor tyrosine kinase 1, NTRK1) and the p75^NTR^ common neurotrophin receptor, a member of the tumor necrosis factor receptor family.[^7^](#fba21143-bib-0007){ref-type="ref"} The precursor for NGF (proNGF) also binds to the membrane protein sortilin, a member of the vacuolar protein sorting 10 protein (Vps10p) family of transmembrane receptors, to induce neuronal differentiation or apoptosis, depending on neuronal subtypes.[^7^](#fba21143-bib-0007){ref-type="ref"} More recently, the expression of NGF and its receptors has been shown in cancer, where they participate in cancer progression.[^8^](#fba21143-bib-0008){ref-type="ref"} For instance, NGF, proNGF and their receptors promote breast cancer cell survival, proliferation, and invasion.[^9^](#fba21143-bib-0009){ref-type="ref"} Recent preclinical studies have also shown a participation of NGF and TrkA in driving the infiltration of human tumors by nerves, which contributes to cancer progression.[^10^](#fba21143-bib-0010){ref-type="ref"}, [^11^](#fba21143-bib-0011){ref-type="ref"}, [^12^](#fba21143-bib-0012){ref-type="ref"}, [^13^](#fba21143-bib-0013){ref-type="ref"}

In cervical cancer, NGF has been linked to perineural invasion,[^14^](#fba21143-bib-0014){ref-type="ref"} a process whereby cancer cells invade nerves, but the extent of NGF expression, and that of its receptors, as well as the clinical significance have not been investigated. In addition, the expression of proNGF and sortilin has not been reported in cervical cancer. The present study aimed to elucidate the immunohistochemical profile and clinicopathological significance of proNGF, NGF, TrkA, p75^NTR^, and sortilin in cervical cancers. We report a significant increase in proNGF, NGF, p75^NTR^, and sortilin in cervical tumors as well as an association with higher grade for proNGF, NGF, and p75^NTR^ in SCC. Interestingly, NGF and TrkA were distinctly overexpressed in SCC, compared to AC and normal cervical tissue. Furthermore, in vitro experiments revealed that targeting TrkA with the Trk tyrosine kinase inhibitor GNF‐5837 resulted in a decreased viability of cervical cancer cells, suggesting a potential utility of TrkA as a therapeutic target.

2. MATERIALS AND METHODS {#fba21143-sec-0002}
========================

2.1. Cervical tissue samples {#fba21143-sec-0003}
----------------------------

High‐density tissue microarrays (TMA, catalogue number CR6161) were obtained from US Biomax Inc and included 294 cases of cervical carcinomas (257 SCC, 30 AC, and 7 unspecified histopathological subtypes) with a combined 28 adjacent normal and normal cervical tissues. The following clinicopathologic information was available for analysis: patient age, histopathological diagnosis, classification of malignant tumors (TNM), stage, and grade. US Biomax Inc quality controls are described as follows. Each single tissue spot on every array slide is individually examined by pathologists certified according to WHO published standardizations of diagnosis, classification, and pathological grade. Each specimen collected was consented to by both hospital and individual. Discrete legal consent was obtained and the rights to hold research uses for any purpose or further commercialized uses were waived. The study was conducted in accordance with the Declaration of Helsinki, and the protocol approved by the Human Research Ethics Committee of the University of Newcastle, Australia (HREC reference: H‐2012‐0063; March 26, 2019).

2.2. Immunohistochemistry and digital quantification {#fba21143-sec-0004}
----------------------------------------------------

Immunohistochemistry was performed as previously described by our laboratory.[^15^](#fba21143-bib-0015){ref-type="ref"} Antibodies against proNGF (1:300 dilution; catalogue number ab9040, Merck Millipore), NGF (1:500 dilution; catalogue number ab52918, Abcam), TrkA (1:200 dilution; catalogue number 2508, Cell Signaling Technology), p75^NTR^ (1:400 dilution; catalogue number 4201, Cell Signaling Technology), and sortilin (0.8 μg/mL; catalogue number ANT‐009, Alomone Labs) and the pan‐neuronal marker PGP9.5 (1:200 dilution; catalogue number ab15503, Abcam) were applied. Negative control testing was also performed using the following antibodies: rabbit IgG, purified serum nonimmune, isotype control (1:200 dilution; catalogue number 20009, Alpha Diagnostic International) or rabbit (DA1E) monoclonal antibody IgG Isotype Control (0.8 μg/mL; catalogue number 3900, Cell Signaling Technology). TMAs were digitized using the Aperio AT2 scanner (Leica Biosystems) at 400× absolute resolution. The HALO™ Image Analysis Platform (Indica Labs) was used to objectively and digitally quantify each TMA core stained by immunohistochemistry. Pixel intensity values were used to determine a h‐score (0‐300) for each tissue core (index calculated as the sum of 3x% of pixels with strong staining +2x% of pixels with intermediate staining +1x% pixels with weak staining).

2.3. Statistical analysis of immunohistochemistry quantification {#fba21143-sec-0005}
----------------------------------------------------------------

H‐scores were analyzed as continuous variables, with summary statistics presented as group level medians and interquartile ranges (IQR). H‐score distributions were compared using the Wilcoxon RankSum (dichotomous) or Kruskal Wallis (multiple comparisons) tests. To assess the primary hypothesis (difference in neurotrophin and receptor expression between benign and malignant samples), a two‐sided alpha of 0.05 was used. To avoid a type 1 error when comparing h‐scores between prespecified demographic and clinicopathological parameters (Table [1](#fba21143-tbl-0001){ref-type="table"}), we adjudicated significance using an adjusted alpha for multiple pairwise comparisons (0.05/6 = 0.008). Analyses were based on complete cases and performed using Stata (version 14.1, Statacorp), with additional figures created using Prism (version 8.2.0, GraphPad Software).

###### 

Associations between NGF, proNGF, TrkA, p75^NTR^ and sortilin expression with clinicopathological parameters in SCC

  Parameter            NGF[^a^](#fba21143-note-0003){ref-type="fn"} intensity   proNGF intensity   TrkA[^b^](#fba21143-note-0004){ref-type="fn"} intensity   p75^NTR^ [^c^](#fba21143-note-0005){ref-type="fn"} intensity   Sortilin intensity                                                                            
  -------------------- -------------------------------------------------------- ------------------ --------------------------------------------------------- -------------------------------------------------------------- -------------------- ----------- ---- -------- ----- ----- --------- ----------- ---- ------- -----
  Age (y)                                                                                          .17                                                                                                                                           .17                       .15                   .11                      .69
  \<50 (n = 154)       100                                                      78‐121                                                                       152                                                            137‐165                          73   52‐106         159   127‐183               61   51‐73   
  ≥50 (n = 103)        93                                                       69‐117                                                                       144                                                            128‐164                          63   42‐106         151   119‐170               61   49‐73   
  Grade                                                                                            **.0053**                                                                                                                                     **.0022**                 .03                   **.0002**                .01
  1 (n = 23)           75                                                       58‐106                                                                       128                                                            117‐151                          80   61‐133         131   112‐156               54   41‐62   
  2 (n = 158)          100                                                      78‐119                                                                       156                                                            139‐166                          73   52‐111         152   126‐178               62   52‐73   
  3 (n = 56)           111                                                      80‐133                                                                       150                                                            136‐169                          63   46‐83          170   149‐190               65   53‐73   
  Tumor size (T)                                                                                   .96                                                                                                                                           .38                       .32                   .9                       .65
  T1 (n = 226)         98                                                       75‐120                                                                       152                                                            134‐166                          70   49‐104         154   127‐179               61   49‐73   
  T2‐T4 (n = 29)       102                                                      76‐115                                                                       147                                                            139‐157                          84   49‐136         160   124‐176               63   58‐71   
  Lymph node (N)                                                                                   .61                                                                                                                                           .29                       .73                   .19                      .85
  Negative (n = 238)   99                                                       75‐120                                                                       151                                                            134‐166                          71   49‐106         155   126‐179               61   49‐72   
  Positive (n = 18)    93                                                       70‐111                                                                       142                                                            132‐158                          60   44‐105         139   123‐168               59   50‐75   
  Stage                                                                                            .68                                                                                                                                           .08                       .97                   .09                      .73
  I + II (n = 229)     99                                                       76‐120                                                                       152                                                            134‐166                          71   49‐105         155   127‐179               61   50‐73   
  III + IV (n = 26)    94                                                       70‐115                                                                       141                                                            132‐157                          64   44‐130         139   114‐168               59   47‐70   

Immunohistochemical staining were quantified and h‐scores were used to compare protein expression levels. Group‐levels medians (interquartile range, IQR) for h‐score staining intensities are presented. Family‐wise alpha significance (*P* value) is .05/6 = .008 using the Mann‐Whitney test (pairwise) or Kruskal‐Wallis test (multiple comparisons, as in the case of "Grade," where the *P* value is assessing an overall within‐group difference). *P* values are presented on the same line as the heading to which they refer. Statistically significant *P* values are shown in bold. Cases missing clinicopathological parameters were not presented in the table or included in statistical analyses.

Nerve growth factor.

Tyrosine kinase receptor A.

p75 neurotrophin receptor.
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2.4. Impact of GNF‐5837 on cervical cancer cell growth and TrkA signaling {#fba21143-sec-0006}
-------------------------------------------------------------------------

### 2.4.1. Cell culture {#fba21143-sec-0007}

HELA cervical cancer cells (catalogue number CCL‐2, American Type Culture Collection) were maintained in DMEM supplemented with 10% (v/v) of fetal bovine serum (FBS) (catalogue number SFBS‐F, Bovogen Biologicals) and 2 mmol/L GlutaMAX supplement (catalogue number 35050061, Thermo Fisher Scientific) in a humidified incubator at 37°C with 5% (v/v) of CO~2~. Routine mycoplasma testing was performed using the MycoAlert Mycoplasma Detection Kit (catalog number LT07‐118; Lonza). Cells were not maintained in culture for longer than 3 months to ensure passage number remained fit for purpose.

### 2.4.2. Protein extraction and western blotting {#fba21143-sec-0008}

Protein extraction from cell lines and western blotting experiments were performed as previously described.[^16^](#fba21143-bib-0016){ref-type="ref"} Complete mini‐protease inhibitor cocktail tablets (catalogue number 4693124001, Roche) and PhosSTOP phosphatase inhibitor tablets (catalogue number 4906837001, Roche) were also used. An anti‐TrkA antibody (catalogue number ANT018, Alomone Labs) was used at a dilution of 1:500 and β‐actin detection (catalogue number A2066, Sigma‐Aldrich) was used at a 1:5000 dilution as the equal loading control. The following antibodies from Cell Signaling Technology were all used at a dilution of 1:500 to assess cellular signaling pathways: anti‐phospho‐TrkA (anti‐p‐TrkA) (Tyr490, catalogue number 9141), anti‐p44/42 MAPK (Erk1/2) (catalogue number 9107), anti‐phospho‐p44/42 MAPK (p‐Erk1/2) (Thr202/Tyr204, catalogue number 4370), anti‐Src (catalogue number 2123), anti‐phospho‐Src (anti‐p‐Src) (Tyr416, catalogue number 2101), anti‐Akt (catalogue number 2920), and anti‐phospho‐Akt (anti‐p‐Akt) (Ser473, catalogue number 4060).

### 2.4.3. GNF‐5837 treatment {#fba21143-sec-0009}

The effect of treatment with GNF‐5837, an oxindole inhibitor of Trk tyrosine kinase activity,[^17^](#fba21143-bib-0017){ref-type="ref"} on HELA cell viability was investigated using the CellTiter‐Blue® Cell Viability Assay (catalogue number G8081, Promega). Briefly, 1 × 10^4^ HELA cells/well were seeded within 100 µL DMEM growth media in 96‐well plates and incubated overnight. Cells were then treated with 100 µL GNF‐5837 (catalogue number SML0844, Sigma‐Aldrich) to a final concentration of 0‐100 µmol/L as well as 0.1% of DMSO (catalogue number D2650, Sigma‐Aldrich) as the negative control and incubated for 48 hours. About 40 µL of CellTiter‐Blue® Reagent was added to each well and the fluorescent intensity was recorded after 4 hours using the FLUOstar Optima Microplate Reader with a 560(20)~Ex~/590(10)~Em~ filter set (BMG Labtech). Each treatment condition was performed in triplicate and data are presented as mean ± SD from three independent experiments. The sensitivity of GNF‐5837 treatment was calculated using half‐maximal inhibitory concentration (IC50) estimated from the plot of the cell viability (percentage of control) vs increasing log concentrations of GNF‐5837 using Prism (version 8.4.2, GraphPad Software).

3. RESULTS {#fba21143-sec-0010}
==========

Cervical cancers and normal cervical tissues were analyzed by immunohistochemistry (IHC). Representative IHC staining for NGF, proNGF, TrkA, p75^NTR^, sortilin, and nerves are illustrated in Figures [1](#fba21143-fig-0001){ref-type="fig"}, [2](#fba21143-fig-0002){ref-type="fig"}, [3](#fba21143-fig-0003){ref-type="fig"}, [4](#fba21143-fig-0004){ref-type="fig"}, [5](#fba21143-fig-0005){ref-type="fig"}, [6](#fba21143-fig-0006){ref-type="fig"}, respectively. Digital quantification of staining intensities, presented as median h‐scores, are reported in Table [1](#fba21143-tbl-0001){ref-type="table"} and Table [S1](#fba21143-sup-0001){ref-type="supplementary-material"}. The assessment of nerve infiltration is presented in Table [2](#fba21143-tbl-0002){ref-type="table"}. The response of the HELA cervical cancer cell line to the Trk inhibitor GNF‐5837 is shown in Figure [7](#fba21143-fig-0007){ref-type="fig"}.

![NGF expression in cervical cancers and normal cervical tissue. Immunohistochemical staining of NGF in normal cervical tissues (A), adenocarcinomas (AC) (B) and squamous cell carcinomas (SCC) (C, D). Scale bars: 50 μm (A‐D). (E) Digital quantification of NGF expression was performed and h‐scores were calculated. Data are expressed as medians (horizontal line in the center of the box) and box limits indicate the interquartile range (IQR) with the whiskers extending 1.5 times the IQR from the 25th and 75th percentiles; outliers are represented by dots. \**P* \< .005 compared to normal tissue expression, assessed using the Kruskal‐Wallis test with adjustment for multiple comparisons](FBA2-2-398-g001){#fba21143-fig-0001}

![ProNGF expression in cervical cancers and normal cervical tissue. Immunohistochemical staining of proNGF in normal cervical tissues (A), adenocarcinomas (AC) (B) and squamous cell carcinomas (SCC) (C, D). Scale bars: 50 μm (A‐D). (E) Digital quantification of proNGF expression was performed and h‐scores were calculated. Data are expressed as medians (horizontal line in the center of the box) and box limits indicate the interquartile range (IQR) with the whiskers extending 1.5 times the IQR from the 25th and 75th percentiles; outliers are represented by dots. \**P* \< .005 compared to normal tissue expression, assessed using the Kruskal‐Wallis test with adjustment for multiple comparisons](FBA2-2-398-g002){#fba21143-fig-0002}

![TrkA expression in cervical cancers and normal cervical tissue. Immunohistochemical staining of TrkA in normal cervical tissues (A), adenocarcinomas (AC) (B) and squamous cell carcinomas (SCC) (C, D). Scale bars: 50 μm (A‐D). (E) Digital quantification of TrkA expression was performed and h‐scores were calculated. Data are expressed as medians (horizontal line in the center of the box) and box limits indicate the interquartile range (IQR) with the whiskers extending 1.5 times the IQR from the 25th and 75th percentiles, with outliers represented by dots (\**P* \< .005 compared to normal tissue expression, assessed using the Kruskal‐Wallis test with adjustment for multiple comparisons)](FBA2-2-398-g003){#fba21143-fig-0003}

![p75^NTR^ expression in cervical cancers and normal cervical tissue. Immunohistochemical detection of p75^NTR^ in normal cervical tissues (A), adenocarcinomas (AC) (B) and squamous cell carcinomas (SCC) (C, D). Scale bars: 50 μm (A‐D). (E) Digital quantification of p75^NTR^ expression was performed and h‐scores were calculated. Data are expressed as medians (horizontal line in the center of the box) and box limits indicate the interquartile range (IQR) with the whiskers extending 1.5 times the IQR from the 25th and 75th percentiles; outliers are represented by dots. \**P* \< .005 compared to normal tissue expression, assessed using the Kruskal‐Wallis test with adjustment for multiple comparisons](FBA2-2-398-g004){#fba21143-fig-0004}

![Sortilin expression in cervical cancers and normal cervical tissue. Immunohistochemical detection of sortilin in normal cervical tissues (A), adenocarcinomas (AC) (B) and squamous cell carcinomas (SCC) (C, D). Scale bars: 50 μm (A‐D). (E) Digital quantification of sortilin expression was performed and h‐scores were calculated. Data are expressed as medians (horizontal line in the center of the box) and box limits indicate the interquartile range (IQR) with the whiskers extending 1.5 times the IQR from the 25th and 75th percentiles; outliers are represented by dots. \**P* \< .005 compared to normal tissue expression, assessed using the Kruskal‐Wallis test with adjustment for multiple comparisons](FBA2-2-398-g005){#fba21143-fig-0005}

![Detection of nerves in the microenvironment of cervical cancer. Immunohistochemical detection of nerves was performed using the pan‐neuronal marker PGP9.5 in a cohort of 287 cervical cancers and 30 normal cervical tissue samples. (A‐D) Nerves stained for PGP9.5 adjacent to stroma (St) and cancer cells (CC). Immunohistochemical detection of proNGF (E), NGF (F), TrkA (G), p75^NTR^ (H) and sortilin (I) was performed in serial sections containing the same nerve shown in (D). Scale bars: 50 μm](FBA2-2-398-g006){#fba21143-fig-0006}

###### 

Association between the presence of nerves and clinicopathological parameters in cervical carcinomas

  Parameter                     Nerve negative   Nerve positive   *P* value                    
  ----------------------------- ---------------- ---------------- ----------- ---------------- --
  Total cases                                                                                  
  Cancer (n = 287)              208              **(73%)**        79          **(27%)**        
  Cancer histological subtype   .7135                                                          
  Adenocarcinoma (n = 30)       21               **(70%)**        9           **(30%)**        
  Squamous (n = 257)            187              **(73%)**        70          **(27%)**        
  Age (years)                   .7446                                                          
  \<50 (n = 171)                124              **(73%)**        47          **(27%)**        
  ≥50 (n = 116)                 84               **(72%)**        32          **(28%)**        
  Tumor size (T)                .5498                                                          
  T1 (n = 254)                  185              **(73%)**        69          **(27%)**        
  T2‐T4 (n = 31)                21               **(68%)**        10          **(32%)**        
  Missing (n = 2)                                                                              
  Lymph node status (N)         .4211                                                          
  Negative (n = 266)            195              **(73%)**        71          **(27%)**        
  Positive (n = 20)             13               **(65%)**        7           **(35%)**        
  Missing (n = 1)                                                                              
  Stage                         .0529                                                          
  I + II (n = 257)              191              **(75%)**        66          **(25%)**        
  III + IV (n = 28)             16               **(57%)**        12          **(43%)**        
  Missing (n = 2)                                                                              
  Grade                         .4570                                                          
  1 (n = 29)                    23               **(79%)**        6           **(21%)**        
  2 (n = 168)                   125              **(74%)**        43          **(26%)**        
  3 (n = 62)                    47               **(76%)**        15          **(24** **%)**   
  Missing (n = 28)                                                                             

Immunohistochemical staining for the pan‐neuronal marker PGP9.5 was performed on a cohort of normal cervical tissue and cervical carcinomas. Cases were classified as nerve negative vs nerve positive and comparisons were made with clinicopathological parameters. No differences between groups were observed (assessed using the Chi‐square test with a *P* value \< .008). The bold values represent the % of cases.
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![Impact of the GNF‐5837 Trk inhibitor in the HELA cervical cancer cell line. (A) HELA cells were treated with 0‐100 µmol/L grade concentrations of the TrkA inhibitor GNF‐5837 in media containing 10% FBS for 48 hours and a dose response curve was generated to determine an IC~50~ of 12.45 µmol/L. Data are presented as mean ± SD of samples from three independent experiments. (B) Representative images of HELA cells treated with 0‐20 µmol/L grade concentrations of GNF‐5837 for 48 hours. (C) Effect of 0‐20 µmol/L GNF‐5837 on TrkA phosphorylation and downstream cellular signaling. Western blot analysis was performed 48 hours posttreatment with GNF‐5837. The level of phospho‐TrkA (p‐TrkA) and phospho‐Erk1/2 (p‐Erk1/2) both decreased in a dose dependent manner. A 0.1% of DMSO was used as a negative control and β‐actin protein expression was used as an equal loading control](FBA2-2-398-g007){#fba21143-fig-0007}

3.1. NGF is overexpressed and associated with increased grade in cervical SCC {#fba21143-sec-0011}
-----------------------------------------------------------------------------

NGF immunohistochemical staining appeared low in normal cervical tissues (Figure [1A](#fba21143-fig-0001){ref-type="fig"}) while increased in both AC (Figure [1B](#fba21143-fig-0001){ref-type="fig"}) and SCC (Figure [1C,D](#fba21143-fig-0001){ref-type="fig"}). Digital quantification revealed a low NGF expression in normal cervical tissue (h‐score = 42, IQR 32‐55) as compared to both AC (h‐score = 68, IQR 52‐84, *P* \< .0001) and SCC (h‐score = 98, IQR 75‐120, *P* \< .0001) (Figure [1E](#fba21143-fig-0001){ref-type="fig"}; Table [S1](#fba21143-sup-0001){ref-type="supplementary-material"}). In SCC, there was a significant association observed between increased NGF (*P* = .0053) and increasing grade (Table [1](#fba21143-tbl-0001){ref-type="table"}). ProNGF (Figure [2A‐D](#fba21143-fig-0002){ref-type="fig"}) was expressed in the normal cervical epithelium (h‐score = 122, IQR 90‐137), with similar levels found in AC (h‐score = 141, IQR 123‐150) and SCC (h‐score = 151, IQR 134‐164) (Figure [2E](#fba21143-fig-0002){ref-type="fig"}; Table [S1](#fba21143-sup-0001){ref-type="supplementary-material"}). The high level of proNGF staining compared to low level of NGF in the normal cervix suggests that proNGF is not processed into NGF in the normal epithelium. In SCC, there was a significant association between proNGF (*P* = .0022) expression and grade (Table [1](#fba21143-tbl-0001){ref-type="table"}).

3.2. TrkA is overexpressed in cervical SCC {#fba21143-sec-0012}
------------------------------------------

In the normal cervical epithelium, TrkA IHC staining was detected only in the parabasal/basal layer (Figure [3A](#fba21143-fig-0003){ref-type="fig"}); whereas the upper layers of normal epithelium and AC (Figure [3B](#fba21143-fig-0003){ref-type="fig"}) were negative. TrkA was strongly expressed in all SCC cells (Figure [3C,D](#fba21143-fig-0003){ref-type="fig"}). Digital quantification confirmed that TrkA immunoreactivity was low in normal cervical tissue (h‐score = 22, IQR 15‐29) and AC (h‐score = 15, IQR 10‐25) and high in SCC (h‐score = 70, IQR 49‐106, *P* \< .0001) (Figure [3E](#fba21143-fig-0003){ref-type="fig"}; Table [S1](#fba21143-sup-0001){ref-type="supplementary-material"}). No associations were found between TrkA staining and any of the available clinicopathological parameters: age, grade, tumor size, lymph node status or stage (Table [1](#fba21143-tbl-0001){ref-type="table"}).

3.3. p75^NTR^ is associated with increasing grade in cervical SCC {#fba21143-sec-0013}
-----------------------------------------------------------------

IHC staining for p75^NTR^ was observed in the parabasal/basal layer of normal cervical tissue (Figure [4A](#fba21143-fig-0004){ref-type="fig"}) and in stromal and cancer cells of AC (Figure [4B](#fba21143-fig-0004){ref-type="fig"}) and SCC (Figure [4C,D](#fba21143-fig-0004){ref-type="fig"}). However, p75^NTR^ staining intensity was significantly higher in cervical cancer (median h‐score = 152, IQR 125‐178) compared to normal cervical tissue (h‐score = 57, IQR 49‐65, *P* \< .0001) (Figure [4E](#fba21143-fig-0004){ref-type="fig"}; Table [S1](#fba21143-sup-0001){ref-type="supplementary-material"}). The increase in p75^NTR^ staining intensity was observed across both histopathological subtypes (Figure [4E](#fba21143-fig-0004){ref-type="fig"}; Table [S1](#fba21143-sup-0001){ref-type="supplementary-material"}). Interestingly, there was a significant association between increased p75^NTR^ protein expression and increasing grade in SCC (*P* = .0002, Table [1](#fba21143-tbl-0001){ref-type="table"}).

3.4. Sortilin is increased in both AC and SCC of the cervix {#fba21143-sec-0014}
-----------------------------------------------------------

Sortilin immunohistochemical staining was not detected in most normal cervical tissues (Figure [5A](#fba21143-fig-0005){ref-type="fig"}). In cervical cancers, sortilin was detected in cancer cells and not in the stroma of both AC (Figure [5B](#fba21143-fig-0005){ref-type="fig"}) and SCC (Figure [5C,D](#fba21143-fig-0005){ref-type="fig"}). Digital quantification of immunoreactivity indicated that sortilin expression was higher in cervical cancers (h‐score = 61, IQR 50‐73) as compared to normal cervical tissues (h‐score = 31, IQR 27‐40, *P* \< .0001), with both AC (h‐score = 62, IQR 51‐78) and SCC (h‐score = 61, IQR 50‐72) expressing comparable levels (Figure [5E](#fba21143-fig-0005){ref-type="fig"}; Table [S1](#fba21143-sup-0001){ref-type="supplementary-material"}). However, no associations were found between sortilin protein expression and the available clinicopathological parameters: age, grade, tumor size, lymph node status or stage (Table [1](#fba21143-tbl-0001){ref-type="table"}).

3.5. Nerves infiltrate the tumor microenvironment of cervical cancers and express TrkA {#fba21143-sec-0015}
--------------------------------------------------------------------------------------

To investigate the presence of nerve infiltration in cervical cancer, immunohistochemical staining using the neuronal marker PGP9.5 was performed. Typical morphologies of nerves were observed (Figure [6](#fba21143-fig-0006){ref-type="fig"}). Nerves were localized within the tumor microenvironment, adjacent to cancer epithelial cells (Figure [6A‐C](#fba21143-fig-0006){ref-type="fig"}). Cervical carcinomas were classified as either negative or positive for the presence of nerves, and comparisons were made with clinicopathological parameters of the patient cohort. Nerves were detected in 27% of cervical cancers, however, cases with nerves present did not show different clinical or pathological parameters compared to cases with nerves (Table [2](#fba21143-tbl-0002){ref-type="table"}). Interestingly, large nerves within the tumor microenvironment (Figure [6D](#fba21143-fig-0006){ref-type="fig"}) were found to also express TrkA (Figure [6G](#fba21143-fig-0006){ref-type="fig"}), whereas proNGF (Figure [6E](#fba21143-fig-0006){ref-type="fig"}), NGF (Figure [6F](#fba21143-fig-0006){ref-type="fig"}), p75^NTR^ (Figure [6H](#fba21143-fig-0006){ref-type="fig"}), and sortilin (Figure [6I](#fba21143-fig-0006){ref-type="fig"}) were not detected in nerves.

3.6. Cytotoxic effect of the Trk inhibitor GNF‐5837 in cervical cancer cells {#fba21143-sec-0016}
----------------------------------------------------------------------------

To define the impact of TrkA signaling in cervical cancer cells, we treated HELA cells with the Trk inhibitor GNF‐5837 and assessed drug sensitivity, impact on viability and signaling (Figure [7A,B](#fba21143-fig-0007){ref-type="fig"}). The data show that HELA cells are sensitive to GNF‐5837 and that viability is reduced in a dose dependent manner, with an IC~50~ of 12.45 µmol/L (Figure [7A,B](#fba21143-fig-0007){ref-type="fig"}). TrkA phosphorylation and various downstream tumorigenic and metastatic‐related pathways such as Erk, Src, and Akt were also examined following treatment with 0‐20 µmol/L of GNF‐5837 (Figure [7C](#fba21143-fig-0007){ref-type="fig"}). Phosphorylated TrkA (Tyr490) and p‐Erk1/2 (Thr202/Tyr204) were markedly decreased in response to GNF‐5837, in a dose dependent manner, whereas downstream Src and Akt signaling were not altered (Figure [7C](#fba21143-fig-0007){ref-type="fig"}). These results suggest that targeting TrkA signaling can decrease survival of cervical cancer cells.

4. DISCUSSION {#fba21143-sec-0017}
=============

This study has clarified the protein expression of NGF and its receptors TrkA and p75^NTR^ in cervical cancer. In addition, we describe for the first time the protein expression of proNGF and its receptor sortilin in cervical cancer. Prior to immunohistochemical profiling, cBioportal platform[^18^](#fba21143-bib-0018){ref-type="ref"} was used to interrogate 275 complete cases of cervical cancer found within The Cancer Genome Atlas (TCGA).[^19^](#fba21143-bib-0019){ref-type="ref"}, [^20^](#fba21143-bib-0020){ref-type="ref"} The following degree of genetic alterations (amplifications, deletions, and missense mutations) were reported: 1.1% for *NGF*, 2.5% for *NTRK1*, 0% for *NGFR* (p75^NTR^) and 1.8% for *SORT1* (sortilin). Despite these relatively low frequencies, it is now well established in the literature that the level of mRNA does not directly correspond to the observed protein abundance in tumors, as demonstrated in colorectal cancer.[^21^](#fba21143-bib-0021){ref-type="ref"} Multiple global transcriptomic and proteomic analyses have shown that only 30%‐60% of changes in protein levels are directly related to changes in mRNA.[^22^](#fba21143-bib-0022){ref-type="ref"}, [^23^](#fba21143-bib-0023){ref-type="ref"} Genetic alterations and miRNA regulations are crucial to the synthesis and posttranslational modification of proteins and are all key factors that can contribute to the discrepancies observed.[^23^](#fba21143-bib-0023){ref-type="ref"} This emphasizes the need to look for cancer biomarkers at the protein level and we have performed IHC profiling of proNGF, NGF, TrkA, p75^NTR^, and sortilin on a cohort of cervical cancers.

The present study demonstrates that proNGF, NGF, TrkA, p75^NTR^, and sortilin are all overexpressed in cervical cancer compared to normal cervical tissues. Similar immunohistochemical profiles for NGF, TrkA, p75^NTR^, and sortilin have previously been described in breast,[^24^](#fba21143-bib-0024){ref-type="ref"}, [^25^](#fba21143-bib-0025){ref-type="ref"}, [^26^](#fba21143-bib-0026){ref-type="ref"}, [^27^](#fba21143-bib-0027){ref-type="ref"} prostate,[^28^](#fba21143-bib-0028){ref-type="ref"} thyroid,[^15^](#fba21143-bib-0015){ref-type="ref"}, [^29^](#fba21143-bib-0029){ref-type="ref"} and lung cancers,[^30^](#fba21143-bib-0030){ref-type="ref"} suggesting that the upregulation of this family of growth factors and receptors is a common phenotypical feature across a variety of human tumor types. In developing neurons, the activation of TrkA upon NGF binding results in the stimulation of various signaling pathways leading to axonogenesis.[^6^](#fba21143-bib-0006){ref-type="ref"} In the adult, TrkA acts as a pain receptor in sensory neurons and contributes to the transmission of pain signals to the central nervous system.[^31^](#fba21143-bib-0031){ref-type="ref"} Outside of the nervous system, there is accumulating evidence for TrkA expression and tumor‐promotive signaling in several human cancers, including those of the breast,[^26^](#fba21143-bib-0026){ref-type="ref"} oral cavity,[^32^](#fba21143-bib-0032){ref-type="ref"} thyroid[^29^](#fba21143-bib-0029){ref-type="ref"} and lung.[^30^](#fba21143-bib-0030){ref-type="ref"}, [^33^](#fba21143-bib-0033){ref-type="ref"} Our data demonstrate that TrkA is expressed in cervical cancer and most particularly in SCC. Similar to our findings, a recent study has demonstrated that TrkA is also overexpressed in SCC of the lung[^30^](#fba21143-bib-0030){ref-type="ref"} and TrkA fusion proteins have also been implicated in lung cancer progression.[^33^](#fba21143-bib-0033){ref-type="ref"} Importantly, various Trk pharmacological inhibitors are currently undergoing clinical trials in various cancers[^34^](#fba21143-bib-0034){ref-type="ref"}, [^35^](#fba21143-bib-0035){ref-type="ref"}, [^36^](#fba21143-bib-0036){ref-type="ref"} and the present study suggests that these Trk targeting drugs should also be tested in cervical SCC.

The concomitant and increased expression of NGF with TrkA in SCC is suggestive of an NGF‐mediated autocrine loop, potentially involving the secretion of NGF from cervical cancer cells and subsequent signaling through both TrkA and p75^NTR^. An autocrine loop of NGF stimulation in cancer cells involving TrkA has already been demonstrated in breast cancer.[^37^](#fba21143-bib-0037){ref-type="ref"} We also report that the expression of proNGF, NGF and p75^NTR^ was associated with increasing grade in SCC, thus, highlighting potential prognostic value as markers of tumor aggressiveness. No additional associations were found with any of the other clinicopathological parameters of the patients, whereas there could be a dual signaling of NGF, via both TrkA and p75^NTR^, in cervical cancer cells, which warrants further investigation.

In recent years, nerves have emerged as promoters of tumor initiation and progression.[^10^](#fba21143-bib-0010){ref-type="ref"}, [^38^](#fba21143-bib-0038){ref-type="ref"} Nerves infiltrated in the tumor microenvironment are releasing growth promoting factors, such as neurotransmitters, that stimulate cancer growth and metastasis.[^10^](#fba21143-bib-0010){ref-type="ref"} In prostate,[^39^](#fba21143-bib-0039){ref-type="ref"} gastric[^40^](#fba21143-bib-0040){ref-type="ref"} and pancreatic[^41^](#fba21143-bib-0041){ref-type="ref"} cancers, tumor denervation can block tumor progression and similarly to angiogenesis, axonogenesis in the tumor microenvironment is, therefore, increasingly viewed as a new target for innovative therapies.[^10^](#fba21143-bib-0010){ref-type="ref"} Innervation of the tumor microenvironment in cervical cancer has recently been described.[^42^](#fba21143-bib-0042){ref-type="ref"} Nerves infiltrating cervical tumors are of sensory origin and axonogenesis appears to be mediated by cancer‐derived exosomes.[^42^](#fba21143-bib-0042){ref-type="ref"} Our results show that TrkA is expressed in nerves infiltrated in cervical cancer and suggest that similarly to gastric[^11^](#fba21143-bib-0011){ref-type="ref"} and pancreatic[^43^](#fba21143-bib-0043){ref-type="ref"} cancer, NGF and TrkA may be involved in driving nerve infiltration in the tumor microenvironment of cervical cancer. However, further investigations are warranted to explore the molecular mechanism of cervical cancer innervation and the potential role played by NGF and its receptors.

Together, the findings of this study outline the clinicopathological significance of proNGF, NGF and their receptors in cervical cancer. In particular, the overexpression profile of NGF and TrkA in SCC suggests that targeting NGF and TrkA may constitute a targeted therapeutic strategy in this subtype of cervical cancer and further preclinical and clinical investigations are warranted to confirm this hypothesis.
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